Sabina Janciauskiene
Sabine Wrenger
Steffen Günzel
Anna Ricarda Gründing
Heiko Golpon
Tobias Welte- Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
An association between acute-phase proteins (APPs) and cancer has long been established and there are numerous reports correlating altered levels and/or molecular forms of APPs with different types of cancers. Many authors have shown a positive correlation between high levels of APPs, like alpha1-antitrypsin (AAT), and unfavorable clinical outcome in cancers. Conversely, others proposed that high levels of APPs are probably just a part of nonspecific inflammatory response to cancer development. However, this might not be always true, because many cancerous cells produce or take up exogenous APPs. What is the biological significance of this and what benefit do cancer cells have from these proteins remains largely unknown. Recent data revealed that some APPs, including AAT, are able to enhance cancer cell resistance against anticancer drug-induced apoptosis and autophagy. In this review, we specifically discuss our own findings and controversies in the literature regarding the role of AAT in cancer.
Introduction
The relationship between inflammation, immunity and cancer is widely accepted. The cancer-related inflammatory responses can occur due to the chemotherapy as well as due to the tumor cell migration, invasion, activation of anti-apoptotic signaling pathways, and metastasis (1). Cancer-caused inflammation may result in the activation of transcription factors like nuclear factor-κB, signal transducer and activator of transcription 3, and hypoxia-inducible factor 1α, which further enhances inflammatory response. Accordingly, markers of systemic inflammation, including C-reactive protein (CRP), albumin, neutrophils, lymphocytes, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and cytokines have been shown to be altered in patients with various cancers (2). These changes in local and systemic inflammatory mediators can induce epigenetic changes that favor tumor initiation, and create a milieu to either enhance or suppress cancer development (3).
The hallmarks of cancer-related environment include immune cells, stromal cells (including myofibroblasts), and inflammatory mediators, tissue remodeling and angiogenesis factors, similar like those seen in chronic inflammatory conditions or in tissue repair. Under the influence of cytokines and chemokines, liver but also other cells, like endothelial and epithelial cells, produce acute phase proteins (APPs). Experimental observations suggest that various cytokine combinations may have additive, synergistic, or inhibitory effects on the production of individual APPs (4). On the other hand, APPs per se modulate inflammatory reaction, as can be illustrated by the CRP example. First, pro-inflammatory cytokines/chemokines, like IL-6, TNFα, and IL-8 induce the production and release of CRP (5), but thereafter CRP itself increases the release of these pro-inflammatory mediators. In line, the infusion of recombinant human CRP into healthy volunteers was found to result in a significant induction of serum levels of the IL-6 and IL-8 as well as amyloid A, phospholipase A, and coagulation markers (6). These observations support a notion that CRP, but also other APPs, are not only markers of inflammation. The functions of APPs are important in trapping of microorganisms and their products, in activating the complement system, in neutralizing enzymes, scavenging free hemoglobin and radicals, and in modulating the host’s immune response. Thus, APPs actively participate in the development and resolution of inflammation, and the overall profiles of APPs seem to depend on the nature of the initial inflammatory event, and how this event induces a systemic protein/cytokine response.
Elevated levels of APPs in patients with a variety of cancers were suggested to serve as prognostic or diagnostic markers in the context of clinical examinations. Interestingly, many types of cancer can express but also take up exogenous APPs, which may influence drug resistance, cancer progression and metastasis (7). For example, recent data have shown that the property of cancer cells to produce serum amyloid A enhances their resistance to T-cell immunity due to the activation of immunosuppressive granulocytes (8, 9).
The relationship between tumorigenesis and altered levels of circulating or tumor-associated APPs, such as haptoglobin, ceruloplasmin, CRP, alpha-2 macroglobulin, alpha-1-acid glycoprotein, plasminogen activator inhibitor-1 and alpha-1-antitrypsin has been reported (Table 1).
Table 1 Acute phase proteins in cancer.
Single APPs are used as biomarkers, especially for cancer prognosis and diagnosis of complications to anticancer treatments. However, clinical studies show that the inflammatory phenotype (i.e., the APPs/cytokine profile) differs between patients not only with different malignancies but also with the same malignant disease (53). Therefore, we and other scientists think that APPs may become more valuable biomarkers if used in combinations or used with other acute phase markers, as a part of an acute phase profile. So far, the most commonly investigated prognostic markers were CRP, albumin, and the CRP: albumin ratio.
Regarding single APPs, an extensive literature supports the pro-tumorigenic activity of plasminogen activator inhibitor 1 (PAI-1, Serpin E1) (54). Clinical studies have shown that higher expression of PAI-1 positively correlates with a poor clinical outcome in patients with breast, ovarian, bladder, colon and non-small cell lung cancers (NSCLC) (26). A number of experimental studies described PAI-1 as an anti-apoptotic protein and a stimulator of angiogenesis (27, 28). On the other hand, employment of small molecule or antibody inhibitors of PAI-1 so far provided no evidence that inhibition of PAI-1 could have any therapeutic effect in cancer patients (29, 30). Likewise, another protease inhibitor, alpha1-antitrypsin (AAT, Serpin A1) has been identified as a prognostic marker of tumor recurrence and prognosis. Our recent results obtained from more than 300 patients with NSCLC revealed that higher serum levels of AAT are prognostic for the patient’s worse outcome (36). Nevertheless, studies regarding the role of AAT in lung cancer are contradictory. Some demonstrate a direct relationship between high levels of AAT and the risk of lung cancer (36, 37) while opposite, others associate genetic AAT deficiency with an increased risk of lung cancer development (55). In this review, we specifically discuss our own findings and controversies in the literature regarding the role of AAT in lung cancer. Insights gained into the action of AAT towards lung cancer cells could be exploited for the future understanding of APPs’ role in tumorigenesis.
Overexpression or Deficiency of Human AAT, Which One Is Related to Tumorigenesis
AAT Functions Beyond Serine Protease Inhibition
Human alpha1-antitrypsin (AAT), a member of the serpin (serine protease inhibitor) superfamily, is an acute phase glycoprotein and the best recognized inhibitor of neutrophil elastase. Various studies show that AAT also inhibits the activity of metalloproteases and caspases that play an essential role in cell apoptosis. AAT is a product of SERPINA1 gene mainly expressed by hepatocytes and monocytes/macrophages. Its expression is regulated by interleukin 6-type cytokines. Both genetic and environmental factors influence an individual’s basal level of AAT, and thus circulating AAT in apparently healthy people can vary from 1 to 2 g/L (56).
Experimental and clinical studies provide evidence that AAT expresses broad anti-inflammatory and immunomodulatory properties, some of which unrelated to protease inhibition. For example, AAT interacts and builds complexes with various inflammation-related ligands including chemokines IL-8 and LTB4, complement factors, and heat-shock proteins (57–60). Moreover, AAT regulates cellular adhesion, chemotaxis, and wound healing and modulates signaling pathways to promote cell proliferation and angiogenesis (61).
AAT Favors Cancer Development
During chronic inflammation, which is a driving force in cancer development, increased levels and functional activity of AAT can rescue not only normal but also cancer cells. Indeed, AAT seems to be involved in the metastatic outgrowth of various cancer types including ovarian, cervical, colorectal, breast, and lung adenocarcinomas (38–42). Elevated plasma levels of AAT have been reported in patients with Hodgkin’s lymphoma, pancreas, prostate, cervix, ovary, breast, larynx, colorectal, and other carcinomas, and proposed to be useful as prognostic factors (43–52). In breast cancer a high level of AAT has been associated with poor clinical prognosis (62). Furthermore, AAT seems to be directly involved in metastasis of ovarian, cervical, colorectal, breast, and lung adenocarcinomas (39, 40). Given an increasing body of research in this area, with pro-tumorigenic claims about AAT, we and others raised the hypothesis that individuals with inherited AAT deficiency might have a lower risk of developing cancer.
AAT Deficiency—Protects or Predisposes to Cancer Development
The deficiency, defined as an AAT blood level less than 35% of the mean expected value, is usually associated with Z allele (point mutation Lys342Glu), and less frequently with combinations of S (Lys264Val) or null alleles (63). Severe AAT deficiency predisposes to early onset of chronic obstructive pulmonary disease with emphysema, to liver cirrhosis at any age, neutrophilic panniculitis, systemic vasculitis, and possibly other inflammatory disease risks (64, 65). Severe AAT deficiency is a risk factor of developing hepatocellular carcinomas because of the damage of hepatocytes caused by retained intracellular polymers of mutant AAT protein, and an inappropriate hepatocellular regeneration. Data from the Swedish National AAT Deficiency Register revealed hepatocellular cancer diagnosis in 32 (2%) out of 1,595 individuals with ZZ AAT deficiency (66). Nevertheless, a risk of hepatocellular carcinoma in AAT deficiency is difficult to quantify because of a global variation in AAT genetics and the incidences of liver cancer (67).
In contrast, there are other reports showing that AAT deficiency people have lower or no increase in risk of developing lung and probably other types of cancers. For example, results from a cross-sectional survey study conducted among 720 AAT deficient people of the Alpha-1 Foundation Research Registry at the Medical University of South Carolina have shown that only 8 (1.1%) of participants have a diagnosis of lung cancer. In line, the comparison of 1585 ZZ AAT deficient subjects from Swedish AAT Deficiency Register and 5,999 population-based controls showed that death due to cancer in general was lower among ZZ individuals compared to the controls, i.e. 11% versus 33%. Pulmonary carcinoma accounted for 1% of the causes of death in ZZ individuals and 4% in the controls (68). There are ongoing clinical studies designed to downregulate endogenous AAT expression within hepatocytes by using small-interfering RNA (siRNA) based drugs (69–71). These studies aim to cure/prevent liver disease in individuals with inherited AAT deficiency caused by intrahepatic accumulation of mutant AAT (63). Hypothetically, this approach of a temporal elimination of AAT protein synthesis might be helpful in the field of cancer and warrants further investigations.
Therapy With Human Plasma AAT Shows No Risk for Cancer Development
It is important to point out that the therapy with human plasma AAT used for over three decades to treat patients with inherited AAT deficiency-related emphysema does not rise tumor development rates. In fact, if untreated, individuals with inherited AAT deficiency seem to have higher risk of developing lung (72), gastrointestinal (73), and liver cancers (74). Likewise, few studies in patients with colorectal and gastric cancer found less AAT in both tissues and serum than in normal counterparts (75, 76). Therefore, one needs carefully consider differences between non-tumor and tumor-related environmental settings. The involvement of AAT in tumorigenesis may strongly depend on cancer cell properties as well as on the concentration and molecular forms of AAT, which are influenced by genetic and microenvironmental factors. For example in the B16-F10 lung metastasis mice model, Guttman and co-authors provided experimental evidence that NK cell-sensitive tumors are unaffected whereas CD8+ T cell-sensitive tumors can be significantly inhibited by the treatment with human AAT (77). It is also important to notify, that during inflammatory conditions AAT can undergo post-translational modifications like S-nitrosylation on its single surface cysteine residue, forming S-NO-AAT, a reducer of tumor cell viability (78).
Role of AAT in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is one of the most common lung cancers worldwide, and about 70% of patients with this cancer present with advanced or metastatic disease at the time of diagnosis (79). Hitherto, there are only limited studies addressing the role of AAT in lung cancer (36, 37, 55). Therefore, to gain further insights into this matter, Schwarz et al. investigated the effects of extracellular AAT on NSCLC cell behavior, in vitro (80). By comparing cancer cells grown in a regular medium versus medium supplemented with AAT, authors found that in the presence of physiological concentrations (0.5–1 mg/ml) of AAT cells acquire better pro-tumorigenic properties, and second that AAT strongly enhances cancer cell resistance against staurosporine-induced toxicity (80).
Staurosporine is a nonspecific protein kinase inhibitor derived from Streptomyces staurosporeus that can trigger cancer cell death through activation of both, apoptosis and autophagy pathways. Several lines of evidence indicate a cross-talk or mutual function between autophagy and apoptosis (81). As an inducer of apoptosis, staurosporine specifically acts through the activation of the mitochondrial apoptotic pathway, which is mainly controlled by Bak and Bax proteins (82, 83). When activated, these proteins can form pores on the mitochondrial outer membrane causing cytochrome c release that binds to apoptotic protease activating factor 1 (Apaf-1) and induces its oligomerization, known as the apoptosome formation. The apoptosome promotes cleavage of procaspase-9 into active caspase-9 which in turn activates caspases-3 and -7 to execute the final steps of apoptosis (84) (Figure 1).
Figure 1 Hypothetical model showing how alpha1-antitrypsin (AAT) may affect staurosporine (STS)-induced apoptosis and autophagy in NSCLC cells. Intracellular entry of AAT occurs constitutively based on lipid raft independent pathways, namely clathrin-mediated, or lipid rafts-dependent, which include caveolae- and flotilin-dependent endocytosis. The AAT could be sequestered into clathrin-coated pits by binding to LRP1 (low-density lipoprotein receptor related protein 1) and SR-BI (scavenger receptor class b type I). Alternatively, AAT can associate with caveolin or flotilin 1/2-postive lipid rafts. All entry pathways might generate AAT-containing vesicles fusing with early endosomes and lysosomes from which—by unknown mechanisms - AAT escapes into the cytoplasm (green structure). There, AAT could affect cancer cell responses to cytotoxic drugs, like STS (staurosporine). STS activates autophagy by inhibiting mTOR (mammalian target of rapamycin), which allows Beclin-1/PI 3-kinase complex formation, increases LC3-II/LC3-I ratio, p62 degradation in autolysosomes and downregulation of Fli I (Flightless I), a controller of p62-LC3 interaction. Indeed, AAT seems to block different steps required for STS to induce autophagy. Potentially, AAT may also interfere with Atg5-Atg12 complex required for the formation of autophagosomes or recruitment of LC-3 to autophagosomes (green structures). As an inducer of apoptosis, STS acts through the activation of the mitochondrial apoptotic pathway. STS causes the aggregation of Bax/Bak and the release of cytochrome c that binds to Apaf-1 (apoptotic protease-activating factor 1) allowing apoptosome assembly and the recruitment of procaspase-9 to the apoptosome. In this scenario AAT might inhibit activation of procaspases-8, -9, -3 preventing Beclin-1/Atg5 degradation and activation of CAD (caspase-activated DNase). A crosstalk between STS-induced autophagy and apoptosis is in part mediated by p62 and beclin-1. Finding that AAT by itself strongly reduces p62 levels but prevents p62 reduction in STS-treated cells suggests that cancer cells utilize AAT to regulate apoptosis and autophagy dependent on the situation. Under basal conditions, AAT as a reducer of p62 protein levels (also important for the activation of procaspase-8), might activate autophagy as a cytoprotective pathway. In the setting when cancer cells face pro-apoptotic activation, autophagy inhibition may become a strategy to escape apoptosis.
AAT Inhibits Staurosporine-Induced NSCLC Cell Apoptosis
According to the results from Schwarz et al., staurosporine-induced NSCLC cell apoptosis was completely hampered in the presence of AAT. More detailed investigations revealed that AAT prevented the cleavage of procaspase-3, a precursor of caspase-3 which is one of the most deleterious executioner caspases in apoptosis pathway (80). As yet, the anti-apoptotic effects of AAT have been mostly attributed to the direct inhibition of caspase-3 activity. Investigators reported that exogenous AAT reduces the activity of caspase-3 in ß-cells, lung endothelial and epithelial cells, cardiomyocytes and neutrophils (85–88), and that AAT inhibits active caspase-3 by forming an AAT-caspase-3-complex (89). In cell-free assays, AAT was also demonstrated to inhibit other executioner caspases, especially caspases-6 and -7, but not the initiator caspases, like caspase-9 (90). However, the results presented by Schwarz et al., indicate that protective effects of AAT against staurosporine-induced NSCLC cells apoptosis might be earlier in the apoptosis pathway than the inhibition of executioner caspases. In concordance, a recent study has shown that AAT significantly suppresses cytokine-induced cleavage of procaspase-9 in human islets (91).
Crosstalk Between Apoptosis and Autophagy
Several autophagy proteins are substrates for caspase-induced apoptosis. For example, caspase-3 and -9-mediated cleavage of Atg5 (E2-like enzyme is required for the formation of autophagosomes) and beclin-1 (implicated in the autophagic programmed cell death) switches autophagy to apoptosis (92). Atg5 has also been found to be cleaved by calpain and translocate to the mitochondria to contribute to the release of cytochrome c. Previous finding that AAT inhibits calpain activity in human neutrophils (93) allows speculating that AAT may protect cancer cells via inhibition of other proteases than caspases.
AAT Inhibits Staurosporine-Induced Autophagy in NSCLC Cells
The mechanism(s) by which AAT helps lung cancer cells to acquire resistance towards staurosporine-induced apoptosis can also involve a shift of the balance towards anti-apoptotic proteins. As a matter of fact, the overexpression of AAT protein in lung cancer cell lines resulted in increased Bcl-2 and decreased beclin-1 levels (94). Thus, AAT may promote cancer cell survival by increasing Bcl-2, an anti-apoptotic, membrane associated protein (95) and by inhibiting beclin-1-dependent autophagy and apoptosis (96–99).
As already mentioned above, similarly to other anticancer agents, staurosporine can induce cancer cell death by simultaneous activation of apoptosis and autophagy (100). Autophagy may serve as a backup process for apoptosis—to enhance and/or contribute to the apoptosis (101–103). Autophagy involves the formation of double-membraned structures known as autophagosomes responsible for the engulfment of cargoes that are subsequently degraded after fusion with lysosomes (104). Autophagosome formation involves a set of proteins named Atg (autophagy-related) that orchestrate autophagosome initiation and biogenesis. Currently, the light chain 3 (LC3) is considered as one of the best autophagosome markers because the amount of LC3-II reflects the number of autophagosomes (105). Again, the LC3-II amount as well as LC3-II/LC3-I ratio not necessarily mirrors the autophagic activity, since the amount of LC3-II might increase not only due to autophagy activation but also due to the inhibition of autophagosome degradation. Therefore, for monitoring autophagic activity is used p62 (known as sequestosome-1), autophagic substrate receptor that is constantly being degraded by autophagy (106, 107). The reduced phosphorylation of mTOR is one more factor well reflecting the activation of autophagic flux (108). Results by Schwarz et al. confirmed that staurosporine added to NSCLC cells activates autophagy as measured by increase in LC3-II/LC3-I ratio, reduced mTOR activity as shown by dephosphorylated/less phosphorylated ribosomal protein S6 (RP-S6), degradation of p62 and downregulation of Flightless I, controlling the binding activity of p62 to LC3 (80). Clearly, in the presence of AAT all above mentioned markers of autophagy activation were unaffected by staurosporine.
Potential Pro-Tumorigenic Functions of AAT
Because autophagy can promote caspase-independent or caspase-dependent cell death (109–112), a major remaining question is whether effect of AAT on autophagy is independent or dependent of apoptosis. We would like to pay particular attention to the finding that, although AAT significantly prevented the reduction in p62 levels in staurosporine-treated NSCLC cancer cells, AAT by itself strongly reduced p62 protein levels as compared to non-treated controls. p62 is a regulator of selective autophagy (113) and recruiter of caspase-8 on autophagic membranes, which establishes a crosstalk between autophagy and apoptosis (114). Thus, the way by which cancer cells utilize AAT to regulate apoptosis and autophagy, probably is a context dependent. Under basal conditions, autophagy as a cyto-protective pathway can be activated by exogenous AAT whereas in the setting when cancer cells face pro-apoptotic activation, autophagy inhibition by AAT may become a strategy to enhance survival. In fact, earlier Shapira et al. reported that intracellularly synthesized AAT prevents autophagic cell death and that exogenous AAT added to the cells prior to the induction of autophagy by tamoxifen reduces autophagy and cell death (115).
One cannot exclude that AAT may also facilitate cell survival through other mechanisms than modulation of autophagy. For example, study by Seung-Hee Chang et al., found that in AAT-overexpressing L132 cancer cells, the expression of manganese superoxide dismutase (SOD2), a tumor suppressive protein acting via inhibition of cell proliferation and induction of apoptosis (116), was markedly reduced.
Discussion
Taken together, current findings promote a notion that higher levels of AAT either due to the increased intracellular expression or external entry can prevent cancer cell death. In fact, intracellular entry of AAT occurs constitutively in all mammalian cells, including cancer cells. The intracellular endocytosis of AAT may depend on the pathways non-involving lipid rafts, namely clathrin-mediated endocytosis, or pathways that take place in lipid rafts, which include caveolae-mediated endocytosis and flotillin-dependent endocytosis (91, 117, 118) (Figure 1). We and other investigators have previously found that cellular uptake of AAT takes place in lipid rafts (108, 118). We hypothesize that the uptake and subcellular trafficking of AAT might strongly depend on its concentration and the activation status of the cells. The uptake of high concentrations of AAT may involve clathrin-mediated endocytosis whereas lower concentrations of AAT may enter via caveolae pathway. Caveolae, in contrast to clathrin-coated pits, are very heterogeneous and the alterations in caveolae are not only important in tumor heterogeneity but also have a prognostic value (119). Hence, to better understand the role of AAT in tumorigenesis, intracellular entry and processing of AAT, but also other APPs, by cancer cells cannot be denied and warrants more detailed investigations.
Finally, it is important to keep in mind that AAT can modulate activities of different cells acting within tumor microenvironment. For example, fibroblasts are one of the important components of the tumor microenvironment, which participate in remodeling and a crosstalk between cancer cells and infiltrating leukocytes (120). Previously, it has been reported that AAT stimulates fibroblast proliferation and extracellular matrix production (120, 121). Remarkably, decreased p62 expression seems to be crucial for myofibroblast differentiation to support fibrosis and tumor growth (122–124). In line, findings by Schwarz and co-authors show that AAT suppresses p62 levels in lung cancer cells. AAT is also reported to affect leukocyte profiles associated with inflammatory resolution and tissue regeneration (125, 126) and to promote macrophage polarization towards the pro-tumorigenic M2-like profile (126, 127). Unfortunately, the possible influence of AAT on the interactions between tumor and tumor-associated cells, which are of critical importance in tumorigenesis, has been only minimally addressed.
Based on the current knowledge, one can conclude that the involvement of AAT as well as other APPs in cancers can be direct (on cancer cells) or indirect (via cancer associated cells), and dependent on protein concentration, molecular form and tumor microenvironment. APPs may form pro- or anti-cancer host defense response, which needs to be taken into consideration for designing cancer treatments. Future work will have to determine whether some of the APPs contribute to and/or reflect cancer development, therefore representing potential therapeutic targets and/or biomarkers in tumorigenesis.
Author Contributions
SJ and SG wrote the first draft. SW prepared figure and table and helped with manuscript preparation. AG, HG, and TW added comments. All authors contributed to the article and approved the submitted version.
Funding
This work has been supported by funding from the German Center for Lung Research (grant 82DZL002A1).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Nickoloff BJ, Ben-Neriah Y, Pikarsky E. Inflammation and cancer: is the link as simple as we think? J Invest Dermatol (2005) 124:x–xiv. doi: 10.1111/j.0022-202X.2005.23724.x
2. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol (2013) 88:218–30. doi: 10.1016/j.critrevonc.2013.03.010
3. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature (2001) 411:375–9. doi: 10.1038/35077241
4. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med (1999) 340:448–54. doi: 10.1056/NEJM199902113400607
5. Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol (2018) 9:754. doi: 10.3389/fimmu.2018.00754
6. Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res (2005) 96:714–6. doi: 10.1161/01.RES.0000163015.67711.AB
7. Orr WS, Malkas LH, Hickey RJ, Sandoval JA, Veas F. Acute Phase Proteins as Cancer Biomarkers. In:. Acute Phase Proteins as Early Non-Specific Biomarkers of Human and Veterinary Diseases. Edn ed. Rijeka, Croatia, Intech: London, UK (2011). p. 408.
8. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol (2010) 11:1039–46. doi: 10.1038/ni.1942
9. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol (2011) 11:802–7. doi: 10.1016/j.intimp.2011.01.003
10. Arredouani M, Matthijs P, Van Hoeyveld E, Kasran A, Baumann H, Ceuppens JL, et al. Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology (2003) 108:144–51. doi: 10.1046/j.1365-2567.2003.01569.x
11. Lu J, Wang Y, Yan M, Feng P, Yuan L, Cai Y, et al. High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer. Oncotarget (2016) 7:41758–66. doi: 10.18632/oncotarget.9676
12. Maffei M, Funicello M, Vottari T, Gamucci O, Costa M, Lisi S, et al. The obesity and inflammatory marker haptoglobin attracts monocytes via interaction with chemokine (C-C motif) receptor 2 (CCR2). BMC Biol (2009) 7:87. doi: 10.1186/1741-7007-7-87
13. Saeed SA, Denning-Kendall PA, McDonald-Gibson WJ, Collier HOJ. Human haptoglobin: an endogenous inhibitor of prostaglandin synthase. In: Willoughby DA, Giroud JP, editors. Inflammation: Mechanisms and Treatment, 4. Edn ed. Cham, Switzerland: Springer Netherlands (1980). p. 873.
14. Tai CS, Lin YR, Teng TH, Lin PY, Tu SJ, Chou CH, et al. Haptoglobin expression correlates with tumor differentiation and five-year overall survival rate in hepatocellular carcinoma. PloS One (2017) 12:e0171269. doi: 10.1371/journal.pone.0171269
15. Cho WC, Yip TT, Cheng WW, Au JS. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer (2010) 102:1731–5. doi: 10.1038/sj.bjc.6605700
16. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli FA, et al. Serum amyloid A: a novel biomarker for endometrial cancer. Cancer (2010) 116:843–51. doi: 10.1002/cncr.24838
17. Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, et al. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem (2006) 54:63–73. doi: 10.1369/jhc.5A6645.2005
19. Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res (2011) 10:1383–95. doi: 10.1021/pr101154j
20. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, et al. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem (2010) 58:1015–23. doi: 10.1369/jhc.2010.956821
21. Ferrin G, Rodriguez-Peralvarez M, Aguilar-Melero P, Ranchal I, Llamoza C, Linares CI, et al. Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis. PloS One (2015) 10:e0118527. doi: 10.1371/journal.pone.0118527
22. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res (2002) 62:4854–9.
23. Arumanayagam M, Wong FW, Rogers M, Swaminathan R. Serum ceruloplasmin, plasma copper concentration and copper to ceruloplasmin ratio in cervical carcinoma. Gynecol Obstet Invest (1993) 35:175–8. doi: 10.1159/000292694
24. Han IW, Jang JY, Kwon W, Park T, Kim Y, Lee KB, et al. Ceruloplasmin as a prognostic marker in patients with bile duct cancer. Oncotarget (2017) 8:29028–37. doi: 10.18632/oncotarget.15995
25. Ohbatake Y, Fushida S, Tsukada T, Kinoshita J, Oyama K, Hayashi H, et al. Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin. Clin Exp Med (2016) 16:585–92. doi: 10.1007/s10238-015-0387-9
26. Schmitt M, Harbeck N, Brunner N, Janicke F, Meisner C, Muhlenweg B, et al. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn (2011) 11:617–34. doi: 10.1586/erm.11.47
27. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol (2001) 152:777–84. doi: 10.1083/jcb.152.4.777
28. Schneider DJ, Chen Y, Sobel BE. The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost (2008) 100:1037–40. doi: 10.1160/TH08-04-0234
29. Li S, Wei X, He J, Tian X, Yuan S, Sun L. Plasminogen activator inhibitor-1 in cancer research. Biomed Pharmacother (2018) 105:83–94. doi: 10.1016/j.biopha.2018.05.119
30. Rouch A, Vanucci-Bacque C, Bedos-Belval F, Baltas M. Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview. Eur J Med Chem (2015) 92:619–36. doi: 10.1016/j.ejmech.2015.01.010
31. Shrotriya S, Walsh D, Nowacki AS, Lorton C, Aktas A, Hullihen B, et al. Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. PloS One (2018) 13:e0202555. doi: 10.1371/journal.pone.0202555
32. Yang JR, Xu JY, Chen GC, Yu N, Yang J, Zeng DX, et al. Post-diagnostic C-reactive protein and albumin predict survival in Chinese patients with non-small cell lung cancer: a prospective cohort study. Sci Rep (2019) 9:8143. doi: 10.1038/s41598-019-44653-x
33. Chen X, Kong X, Zhang Z, Chen W, Chen J, Li H, et al. Alpha-2-macroglobulin as a radioprotective agent: a review. Chin J Cancer Res (2014) 26:611–21. doi: 10.3978/j.issn.1000-9604.2014.09.04
34. Guo L, Ren H, Zeng H, Gong Y, Ma X. Proteomic analysis of cerebrospinal fluid in pediatric acute lymphoblastic leukemia patients: a pilot study. Onco Targets Ther (2019) 12:3859–68. doi: 10.2147/OTT.S193616
35. Kanoh Y, Ohara T, Egawa S, Baba S, Akahoshi T. Prognostic potential of a PSA complex in sera of prostate cancer patients with alpha2-macroglobulin deficiency. J Clin Lab Anal (2008) 22:302–6. doi: 10.1002/jcla.20260
36. Ercetin E, Richtmann S, Delgado BM, Gomez-Mariano G, Wrenger S, Korenbaum E, et al. Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC. Cancers (Basel) (2019) 11:1306. doi: 10.3390/cancers11091306
37. El-Akawi ZJ, Abu-Awad AM, Sharara AM, Khader Y. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients. Neuroendocrinol Lett (2010) 31:113–6.
38. Mbeunkui F, Metge BJ, Shevde LA, Pannell LK. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J Proteome Res (2007) 6:2993–3002. doi: 10.1021/pr060629m
39. Normandin K, Peant B, Le Page C, de Ladurantaye M, Ouellet V, Tonin PN, et al. Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clin Exp Metastasis (2010) 27:55–69. doi: 10.1007/s10585-009-9303-6
40. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, et al. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest (2008) 118:352–63. doi: 10.1172/JCI32040
41. Wozniak B, Mila-Kierzenkowska C, Wozniak A, Drewa G, Soponska M, Drewa T, et al. The effect of combined therapy on activity of cathepsin D and alpha-1-antitrypsin in the blood serum of women with cervical cancer. Eur J Gynaecol Oncol (2008) 29:617–9.
42. Zelvyte I, Wallmark A, Piitulainen E, Westin U, Janciauskiene S. Increased plasma levels of serine proteinase inhibitors in lung cancer patients. Anticancer Res (2004) 24:241–7.
43. Brkic S, Salkic A, Nuhbegovic S, Brkic F, Umihanic S. Influence of surgical therapy on serum values of alpha 1-antitrypsin in patients with head and neck tumors. Med Arh (2011) 65:99–101.
44. Dabrowska M, Kemona H, Prokopowicz J, Kiluk S. Serum concentration of alpha-2-macroglobulin, alpha-1-antitrypsin and alpha-1-antichymotrypsin [correction of alpha-2-antichymotrypsin] in patients with Hodgkin’s disease. Mater Med Pol (1992) 24:28–30.
45. Krecicki T, Leluk M. Acute phase reactant proteins–an aid to monitoring surgical treatment of laryngeal carcinoma. J Laryngol Otol (1992) 106:613–5. doi: 10.1017/s002221510012033x
46. Latner AL, Turner GA, Lamin MM. Plasma alpha-1-antitrypsin levels in early and late carcinoma of the cervix. Oncology (1976) 33:12–4. doi: 10.1159/000225093
47. Perez-Holanda S, Blanco I, Menendez M, Rodrigo L. Serum concentration of alpha-1 antitrypsin is significantly higher in colorectal cancer patients than in healthy controls. BMC Cancer (2014) 14:355. doi: 10.1186/1471-2407-14-355
48. Tountas Y, Sparos L, Theodoropoulos C, Trichopoulos D. Alpha 1-antitrypsin and cancer of the pancreas. Digestion (1985) 31:37–40. doi: 10.1159/000199175
49. Vasishta A, Baker PR, Preece PE, Wood RA, Cuschieri A. Serum proteinase-like peptidase activities and proteinase inhibitors in women with breast disease. Eur J Cancer Clin Oncol (1984) 20:197–202. doi: 10.1016/0277-5379(84)90184-6
50. Ward AM, Cooper EH, Houghton AL. Acute phase reactant proteins in prostatic cancer. Br J Urol (1977) 49:411–8. doi: 10.1111/j.1464-410x.1977.tb04168.x
51. Warwas M, Gerber J, Pietkiewicz A. Haptoglobin and proteinase inhibitors in the blood serum of women with inflammatory, benign and neoplastic lesions of the ovary. Neoplasma (1986) 33:79–84.
52. Zbroja-Sontag W. Defense proteins and immune complexes in the blood serum of women with inflammatory and neoplastic lesions of the ovary. Am J Reprod Immunol (1983) 4:11–20. doi: 10.1111/j.1600-0897.1983.tb00247.x
53. Bruserud O, Aarstad HH, Tvedt THA. Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer-What Can We Learn from the Hematological Experience? Cancers (Basel) (2020) 12:1966. doi: 10.3390/cancers12071966
54. Kubala MH, DeClerck YA. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding. Cancer Metastasis Rev (2019) 38:483–92. doi: 10.1007/s10555-019-09806-4
55. Torres-Duran M, Ruano-Ravina A, Parente-Lamelas I, Abal-Arca J, Leiro-Fernandez V, Montero-Martinez C, et al. Alpha-1 Antitrypsin Deficiency and Lung Cancer Risk: A Case-Control Study in Never-Smokers. J Thoracic Oncol (2015) 10:1279–84. doi: 10.1097/JTO.0000000000000609
56. Ferrarotti I, Poplawska-Wisniewska B, Trevisan MT, Koepke J, Dresel M, Koczulla R, et al. How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency? PloS One (2015) 10:e0135316. doi: 10.1371/journal.pone.0135316
57. O’Brien ME, Fee L, Browne N, Carroll TP, Meleady P, Henry M, et al. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency. Thorax (2020) 75:321–30. doi: 10.1136/thoraxjnl-2019-214076
58. Finotti P, Pagetta A. A heat shock protein70 fusion protein with alpha1-antitrypsin in plasma of type 1 diabetic subjects. Biochem Biophys Res Commun (2004) 315:297–305. doi: 10.1016/j.bbrc.2004.01.058
59. Bergin DA, Reeves EP, Meleady P, Henry M, McElvaney OJ, Carroll TP, et al. alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest (2010) 120:4236–50. doi: 10.1172/JCI41196
60. O’Dwyer CA, O’Brien ME, Wormald MR, White MM, Banville N, Hurley K, et al. The BLT1 Inhibitory Function of alpha-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling. J Immunol (2015) 195:3628–41. doi: 10.4049/jimmunol.1500038
61. Janciauskiene S, Wrenger S, Immenschuh S, Olejnicka B, Greulich T, Welte T, et al. The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions. Front Pharmacol (2018) 9:341. doi: 10.3389/fphar.2018.00341
62. Zhao Z, Ma J, Mao Y, Dong L, Li S, Zhang Y. Silence of alpha1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells. Med Sci Monit (2018) 24:6851–60. doi: 10.12659/MSM.910665
63. Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T. The discovery of alpha1-antitrypsin and its role in health and disease. Respir Med (2011) 105:1129–39. doi: 10.1016/j.rmed.2011.02.002
64. de Serres F, Blanco I. Role of alpha-1 antitrypsin in human health and disease. J Intern Med (2014) 276:311–35. doi: 10.1111/joim.12239
65. Janciauskiene S, Welte T. Well-Known and Less Well-Known Functions of Alpha-1 Antitrypsin. Its Role in Chronic Obstructive Pulmonary Disease and Other Disease Developments. Ann Am Thorac Soc (2016) 13(Suppl 4):S280–8. doi: 10.1513/AnnalsATS.201507-468KV
66. Tanash HA, Piitulainen E. Liver disease in adults with severe alpha-1-antitrypsin deficiency. J Gastroenterol (2019) 54:541–48. doi: 10.1007/s00535-019-01548-y
67. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol (2019) 16:589–604. doi: 10.1038/s41575-019-0186-y
68. Tanash HA, Ekstrom M, Ronmark E, Lindberg A, Piitulainen E. Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits. Eur Respir J (2017) 50:1700198. doi: 10.1183/13993003.00198-2017
69. Hu B, Weng Y, Xia X-H, Liang X-j, Huang Y. Clinical advances of siRNA therapeutics. J Gene Med (2019) 21:e3097. doi: 10.1002/jgm.3097
70. Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Targeted Ther (2020) 5:101. doi: 10.1038/s41392-020-0207-x
71. Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee SS. Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine. Mol Ther Nucleic Acids (2017) 8:132–43. doi: 10.1016/j.omtn.2017.06.005
72. Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Internal Med (2008) 168:1097–103. doi: 10.1001/archinte.168.10.1097
73. Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol (2004) 5:182–90. doi: 10.1016/S1470-2045(04)01414-7
74. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology (2005) 42:514–21. doi: 10.1002/hep.20815
75. Wu JY, Cheng CC, Wang JY, Wu DC, Hsieh JS, Lee SC, et al. Discovery of tumor markers for gastric cancer by proteomics. PloS One (2014) 9:e84158. doi: 10.1371/journal.pone.0084158
76. Xie LQ, Zhao C, Cai SJ, Xu Y, Huang LY, Bian JS, et al. Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J Proteome Res (2010) 9:4701–9. doi: 10.1021/pr100406z
77. Guttman O, Freixo-Lima GS, Kaner Z, Lior Y, Rider P, Lewis EC. Context-Specific and Immune Cell-Dependent Antitumor Activities of alpha1-Antitrypsin. Front Immunol (2016) 7:559. doi: 10.3389/fimmu.2016.00559
78. Miyamoto Y, Akaike T, Maeda H. S-nitrosylated human alpha(1)-protease inhibitor. Biochim Biophys Acta (2000) 1477:90–7. doi: 10.1016/s0167-4838(99)00264-2
79. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clinics Chest Med (2011) 32:605–44. doi: 10.1016/j.ccm.2011.09.001
80. Schwarz N, Tumpara S, Wrenger S, Ercetin E, Hamacher J, Welte T, et al. Alpha1-antitrypsin protects lung cancer cells from staurosporine-induced apoptosis: the role of bacterial lipopolysaccharide. Sci Rep (2020) 10:9563. doi: 10.1038/s41598-020-66825-w
81. Chang SH, Lee HJ, Kang B, Yu KN, Minai-Tehrani A, Lee S, et al. Methylmercury induces caspase-dependent apoptosis and autophagy in human neural stem cells. J Toxicol Sci (2013) 38:823–31. doi: 10.2131/jts.38.823
82. Delbridge AR, Grabow S, Strasser A, Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer (2016) 16:99–109. doi: 10.1038/nrc.2015.17
83. Vince JE, De Nardo D, Gao W, Vince AJ, Hall C, McArthur K, et al. The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1beta Activation. Cell Rep (2018) 25:2339–53 e4. doi: 10.1016/j.celrep.2018.10.103
84. Wu CC, Lee S, Malladi S, Chen MD, Mastrandrea NJ, Zhang Z, et al. The Apaf-1 apoptosome induces formation of caspase-9 homo- and heterodimers with distinct activities. Nat Commun (2016) 7:13565. doi: 10.1038/ncomms13565
85. Gao W, Zhao J, Kim H, Xu S, Chen M, Bai X, et al. alpha1-Antitrypsin inhibits ischemia reperfusion-induced lung injury by reducing inflammatory response and cell death. J Heart Lung Transplant (2014) 33:309–15. doi: 10.1016/j.healun.2013.10.031
86. Hurley K, Lacey N, O’Dwyer CA, Bergin DA, McElvaney OJ, O’Brien ME, et al. Alpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individuals. J Immunol (2014) 193:3978–91. doi: 10.4049/jimmunol.1400132
87. Toldo S, Seropian IM, Mezzaroma E, Van Tassell BW, Salloum FN, Lewis EC, et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol (2011) 51:244–51. doi: 10.1016/j.yjmcc.2011.05.003
88. Zhang B, Lu Y, Campbell-Thompson M, Spencer T, Wasserfall C, Atkinson M, et al. Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes (2007) 56:1316–23. doi: 10.2337/db06-1273
89. Petrache I, Fijalkowska I, Medler TR, Skirball J, Cruz P, Zhen L, et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol (2006) 169:1155–66. doi: 10.2353/ajpath.2006.060058
90. Lockett AD, Van Demark M, Gu Y, Schweitzer KS, Sigua N, Kamocki K, et al. Effect of cigarette smoke exposure and structural modifications on the alpha-1 Antitrypsin interaction with caspases. Mol Med (2012) 18:445–54. doi: 10.2119/molmed.2011.00207
91. Wang J, Gou W, Kim DS, Strange C, Wang H. Clathrin-mediated Endocytosis of Alpha-1 Antitrypsin is Essential for its Protective Function in Islet Cell Survival. Theranostics (2019) 9:3940–51. doi: 10.7150/thno.31647
92. Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta (2013) 1833:3448–59. doi: 10.1016/j.bbamcr.2013.06.001
93. Al-Omari M, Korenbaum E, Ballmaier M, Lehmann U, Jonigk D, Manstein DJ, et al. Acute-phase protein alpha1-antitrypsin inhibits neutrophil calpain I and induces random migration. Mol Med (2011) 17:865–74. doi: 10.2119/molmed.2011.00089
94. Chang S-H, Cho K-C, Yu K-N, Hong S-H, Park S, Lee AY, et al. Alpha 1-antitrypsin activates lung cancer cell survival by acting on cap-dependent protein translation, vesicle-mediated transport, and metastasis. Oncotarget (2016). doi: 10.18632/oncotarget.10695
95. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science (1997) 275:1129–32. doi: 10.1126/science.275.5303.1129
96. Fox JL, MacFarlane M. Targeting cell death signalling in cancer: minimising ‘Collateral damage’. Br J Cancer (2016) 115:5–11. doi: 10.1038/bjc.2016.111
97. Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep (2001) 2:330–5. doi: 10.1093/embo-reports/kve061
98. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell (2005) 122:927–39. doi: 10.1016/j.cell.2005.07.002
99. Shin JY, Hong SH, Kang B, Minai-Tehrani A, Cho MH. Overexpression of beclin1 induced autophagy and apoptosis in lungs of K-rasLA1 mice. Lung Cancer (2013) 81:362–70. doi: 10.1016/j.lungcan.2013.05.009
100. Bampton ET, Goemans CG, Niranjan D, Mizushima N, Tolkovsky AM. The dynamics of autophagy visualized in live cells: from autophagosome formation to fusion with endo/lysosomes. Autophagy (2005) 1:23–36. doi: 10.4161/auto.1.1.1495
101. Kumar D, Shankar S, Srivastava RK. Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms. Mol Cancer (2013) 12:171. doi: 10.1186/1476-4598-12-171
102. Laussmann MA, Passante E, Dussmann H, Rauen JA, Wurstle ML, Delgado ME, et al. Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8. Cell Death Different (2011) 18:1584–97. doi: 10.1038/cdd.2011.27
103. Liao A, Hu R, Zhao Q, Li J, Li Y, Yao K, et al. Autophagy induced by FTY720 promotes apoptosis in U266 cells. Eur J Pharm Sci (2012) 45:600–5. doi: 10.1016/j.ejps.2011.12.014
104. Bento CF, Renna M, Ghislat G, Puri C, Ashkenazi A, Vicinanza M, et al. Mammalian Autophagy: How Does It Work? Annu Rev Biochem (2016) 85:685–713. doi: 10.1146/annurev-biochem-060815-014556
105. Wild P, McEwan DG, Dikic I. The LC3 interactome at a glance. J Cell Sci (2014) 127:3–9. doi: 10.1242/jcs.140426
106. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol (2005) 171:603–14. doi: 10.1083/jcb.200507002
107. Sanchez-Martin P, Komatsu M. p62/SQSTM1 - steering the cell through health and disease. J Cell Sci (2018) 131:jcs222836. doi: 10.1242/jcs.222836
108. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett (2010) 584:1287–95. doi: 10.1016/j.febslet.2010.01.017
109. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Different (2008) 15:171–82. doi: 10.1038/sj.cdd.4402233
110. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 8:741–52. doi: 10.1038/nrm2239
111. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol (2004) 6:1221–8. doi: 10.1038/ncb1192
112. Wang Y, Han R, Liang ZQ, Wu JC, Zhang XD, Gu ZL, et al. An autophagic mechanism is involved in apoptotic death of rat striatal neurons induced by the non-N-methyl-D-aspartate receptor agonist kainic acid. Autophagy (2008) 4:214–26. doi: 10.4161/auto.5369
113. Cha-Molstad H, Yu JE, Feng Z, Lee SH, Kim JG, Yang P, et al. p62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis. Nat Commun (2017) 8:102. doi: 10.1038/s41467-017-00085-7
114. Yan XY, Zhong XR, Yu SH, Zhang LC, Liu YN, Zhang Y, et al. p62 aggregates mediated Caspase 8 activation is responsible for progression of ovarian cancer. J Cell Mol Med (2019) 23:4030–42. doi: 10.1111/jcmm.14288
115. Shapira MG, Khalfin B, Lewis EC, Parola AH, Nathan I. Regulation of autophagy by alpha1-antitrypsin: “a foe of a foe is a friend”. Mol Med (2014) 20:417–26. doi: 10.2119/molmed.2014.00054
116. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother (2005) 59:143–8. doi: 10.1016/j.biopha.2005.03.006
117. Sohrab S, Petrusca DN, Lockett AD, Schweitzer KS, Rush NI, Gu Y, et al. Mechanism of alpha-1 antitrypsin endocytosis by lung endothelium. FASEB J (2009) 23:3149–58. doi: 10.1096/fj.09-129304
118. Subramaniyam D, Zhou H, Liang M, Welte T, Mahadeva R, Janciauskiene S. Cholesterol rich lipid raft microdomains are gateway for acute phase protein, SERPINA1. Int J Biochem Cell Biol (2010) 42:1562–70. doi: 10.1016/j.biocel.2010.06.009
119. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Caveolae and signalling in cancer. Nat Rev Cancer (2015) 15:225–37. doi: 10.1038/nrc3915
120. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer (2020) 20:174–86. doi: 10.1038/s41568-019-0238-1
121. Dabbagh K, Laurent GJ, Shock A, Leoni P, Papakrivopoulou J, Chambers RC. Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways. J Cell Physiol (2001) 186:73–81. doi: 10.1002/1097-4652(200101)186:1<73::AID-JCP1002>3.0.CO;2-Q
122. Reina-Campos M, Shelton PM, Diaz-Meco MT, Moscat J. Metabolic reprogramming of the tumor microenvironment by p62 and its partners. Biochim Biophys Acta – Rev Cancer (2018) 1870:88–95. doi: 10.1016/j.bbcan.2018.04.010
123. Valencia T, Kim JY, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Campos M, et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell (2014) 26:121–35. doi: 10.1016/j.ccr.2014.05.004
124. Yoshida GJ, Azuma A, Miura Y, Orimo A. Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies. Int J Mol Sci (2019) 20:2256. doi: 10.3390/ijms20092256
125. Guttman O, Yossef R, Freixo-Lima G, Rider P, Porgador A, Lewis EC. alpha1-Antitrypsin modifies general NK cell interactions with dendritic cells and specific interactions with islet beta-cells in favor of protection from autoimmune diabetes. Immunology (2014) 144:530–9. doi: 10.1111/imm.12403
126. Lewis EC. Expanding the clinical indications for alpha(1)-antitrypsin therapy. Mol Med (2012) 18:957–70. doi: 10.2119/molmed.2011.00196
Keywords: cancer cells, alpha1-antitrypsin, acute phase proteins, apoptosis, autophagy, cancer microenvironment
Citation: Janciauskiene S, Wrenger S, Günzel S, Gründing AR, Golpon H and Welte T (2021) Potential Roles of Acute Phase Proteins in Cancer: Why Do Cancer Cells Produce or Take Up Exogenous Acute Phase Protein Alpha1-Antitrypsin? Front. Oncol. 11:622076. doi: 10.3389/fonc.2021.622076
Received: 27 October 2020; Accepted: 06 January 2021;
Published: 19 February 2021.
Edited by:
Niels Weinhold, Heidelberg University, GermanyReviewed by:
Yun Dai, First Affiliated Hospital of Jilin University, ChinaKamini Singh, Memorial Sloan Kettering Cancer Center, United States
Copyright © 2021 Janciauskiene, Wrenger, Günzel, Gründing, Golpon and Welte. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sabina Janciauskiene, Janciauskiene.Sabina@mh-hannover.de